Sociedad Americana de Hirudoterapia

Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.

Research article published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportEnsayos clínicosDesarrollo de fármacosSchiffer et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013

Abstract

PURPOSE: To develop an evidence-based guideline on central venous catheter (CVC) care for patients with cancer that addresses catheter type, insertion site, and placement as well as prophylaxis and management of both catheter-related infection and thrombosis. METHODS: A systematic search of MEDLINE and the Cochrane Library (1980 to July 2012) identified relevant articles published in English. RESULTS: The overall quality of the randomized controlled trial evidence was rated as good. There is consistency among meta-analyses and guidelines compiled by other groups as well. RECOMMENDATIONS: There is insufficient evidence to recommend one CVC type or insertion site; femoral catheterization should be avoided. CVC should be placed by well-trained providers, and the use of a CVC clinical care bundle is recommended. The use of antimicrobial/antiseptic-impregnated and/or heparin-impregnated CVCs is recommended to decrease the risk of catheter-related infections for short-term CVCs, particularly in high-risk groups; more research is needed. The prophylactic use of systemic antibiotics is not recommended before insertion. Data are not sufficient to recommend for or against routine use of antibiotic flush/lock therapy; more research is needed. Before starting antibiotic therapy, cultures should be obtained. Some life-threatening infections require immediate catheter removal, but most can be treated with antimicrobial therapy while the CVC remains in place. Routine flushing with saline is recommended. Prophylactic use of warfarin or low-molecular weight heparin is not recommended, although a tissue plasminogen activator (t-PA) is recommended to restore patency to occluded catheters. CVC removal is recommended when the catheter is no longer needed or if there is a radiologically confirmed thrombosis that worsens despite anticoagulation therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnti-Infective AgentsAnticoagulantsCatheter-Related InfectionsCatheterization, Central VenousCentral Venous CathetersHumansMedical OncologyMeta-Analysis as TopicNeoplasmsPractice Guidelines as TopicRandomized Controlled Trials as TopicThrombosis

Resumen

To develop an evidence-based guideline on central venous catheter (CVC) care for patients with cancer that addresses catheter type, insertion site, and placement as well as prophylaxis and management of both catheter-related infection and thrombosis. A systematic search of MEDLINE and the Cochrane...

Por qué esto importa para la hirudoterapia

Este artículo presenta una guía basada en la evidencia sobre el cuidado de catéteres venosos centrales en pacientes con cáncer, abordando el tipo de catéter, el sitio de inserción, la colocación, y la profilaxis y manejo de la infección y trombosis relacionadas con el catéter. Las recomendaciones incluyen el uso de paquetes de medidas (care bundles), catéteres impregnados con antimicrobianos o heparina para uso a corto plazo en grupos de alto riesgo, lavado rutinario con solución salina, y t-PA para restaurar la permeabilidad de los catéteres ocluidos; no se recomienda la warfarina profiláctica ni la heparina de bajo peso molecular. Para el ámbito de la ASH, cualquier relevancia se limita al contexto clínico general del uso de anticoagulantes en dispositivos de acceso vascular. El resumen no menciona sanguijuelas, hirudoterapia ni el secretoma de la sanguijuela, por lo que no existe un vínculo específico con la sanguijuela defendible respecto al ámbito de la ASH.

Citación

Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.

Schiffer et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.